1) the section you refer to is a "risk factors" section, not exactly what you present it as and it seems you misunderstand the purpose of a risk factors section in a disclosure document (yes, people could slip and fall in front of the building, every day we all get older and older and no doubt about it, each day we wake, could be our last);
2) you have more up-to-date reference points in the abundance that give the full and total information, but you only quote the risk factors section out of context, including the JAMA paper, with the SAP, and the multiple videos with doctors explaining the issues fully and completely;
3) You keep talking about "double dosing" as if it's a thing, and you're clearly not understanding something there, and it is exhausting constantly rebutting, but it's too ridiculous not to do it. Leave it out there and the unsophisticated who come here might think they are missing some subtle point. They're not. There is no "double dosing", and placebo patients in this trial are exactly the same as any placebo patients in any other of the contemporaneous trials used for ECA, before they cross over and would be the same for any trial for recurrent gbm.
Bullish
Market Data 
Markets 
AI
